CARGO Therapeutics, Inc. financial data

Symbol
CRGX on Nasdaq
Location
835 Industrial Road, Suite 400, San Carlos, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 6, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.12K % -3.82%
Debt-to-equity 16 % -8.39%
Return On Equity -69.2 % -29.5%
Return On Assets -59.7 % -46.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 48.4M shares +5.36%
Common Stock, Shares, Outstanding 46M shares +11.7%
Entity Public Float 522M USD
Common Stock, Value, Issued 46K USD 0%
Weighted Average Number of Shares Outstanding, Basic 48.1M shares +11%
Weighted Average Number of Shares Outstanding, Diluted 48.1M shares +11%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 114M USD -3.14%
General and Administrative Expense 41.6M USD +13.9%
Operating Income (Loss) -239M USD -55.1%
Net Income (Loss) Attributable to Parent -222M USD -50.1%
Earnings Per Share, Basic -4 USD/shares -116%
Earnings Per Share, Diluted -4 USD/shares -116%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 108M USD -29.8%
Marketable Securities, Current 145M USD -50%
Assets, Current 259M USD -42.3%
Property, Plant and Equipment, Net 1.11M USD -89.5%
Operating Lease, Right-of-Use Asset 22.9M USD -14.8%
Other Assets, Noncurrent 93K USD -97.9%
Assets 259M USD -47.2%
Accounts Payable, Current 8.67M USD +23.7%
Employee-related Liabilities, Current 25K USD -99.3%
Accrued Liabilities, Current 739K USD -86.9%
Liabilities, Current 20.9M USD -20.9%
Operating Lease, Liability, Noncurrent 0 USD -100%
Other Liabilities, Noncurrent 225K USD -10%
Liabilities 20.9M USD -61.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax -9K USD +97.2%
Retained Earnings (Accumulated Deficit) -447M USD -98.4%
Stockholders' Equity Attributable to Parent 238M USD -45.5%
Liabilities and Equity 259M USD -47.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -37.7M USD -25%
Net Cash Provided by (Used in) Investing Activities 35M USD
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 46M shares +11.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.61M USD +99.2%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 108M USD -29.7%
Deferred Tax Assets, Valuation Allowance 89.7M USD +195%
Deferred Tax Assets, Gross 95.6M USD +158%
Operating Lease, Liability 578K USD -97.9%
Depreciation 2.22M USD +3.99%
Payments to Acquire Property, Plant, and Equipment 382K USD -70.4%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -221M USD -49.6%
Lessee, Operating Lease, Liability, to be Paid 584K USD -98.7%
Property, Plant and Equipment, Gross 1.31M USD -90%
Operating Lease, Liability, Current 578K USD -10.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 7.44M USD +3%
Lessee, Operating Lease, Liability, to be Paid, Year One 7.23M USD +54.5%
Operating Lease, Weighted Average Discount Rate, Percent 0.13 pure -7.3%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 14.7M USD -21.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 7.66M USD +3%
Deferred Tax Assets, Operating Loss Carryforwards 20.8M USD +815%
Unrecognized Tax Benefits 4.51M USD +265%
Lessee, Operating Lease, Liability, to be Paid, Year Four 7.89M USD
Operating Lease, Payments 0 USD -100%
Additional Paid in Capital 685M USD +3.49%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares